EWSR1 and sarcoma: Fourteen subjects with EWSR1-NFATc2 fusion positive sarcoma were identified in the Foundation Medicine FoundationCore® (FMI) research database from a total of 1024 EWSR1 fusions, resulting in an overall prevalence of 1.4% among EWSR1 fusion positive sarcomas.